Tag: CMRX

  • Healthcare Unusual Volume: Urologix Inc (OTCMKTS:ULGX), Depomed Inc (NASDAQ:DEPO), DURECT Corporation (NASDAQ:DRRX), Chimerix (NASDAQ:CMRX)

    On Feb 04, 2014, Urologix, Inc. (otcqb:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced that it has secured an extension to June 30, 2014 of its credit facility with Silicon Valley Bank (“SVB”), the commercial banking division of SVB Financial Group. The line of credit with SVB allows borrowing by the Company of up to the lesser of $2.0 million or the defined borrowing base consisting of 80% of eligible accounts receivable. Urologix Inc (OTCMKTS:ULGX) stock opened at $0.16 in last trading session, and closed at $0.170, trading in the range of $0.14 – $0.17.

    Depomed (NASDAQ:DEPO) was upgraded by research analysts at EVA Dimensions from an “underweight” rating to a “hold” rating in a report released on Thursday, Stock Ratings News reports. Depomed Inc (NASDAQ:DEPO) shares closed at $14.94 on last trade day, by gaining 10.67%. Stock 52 week range is $4.99 – $15.39. Company’s market capitalization is $851.38 million.

    On March 7, 2014, Harwood Feffer LLP is investigating potential claims against DURECT Corporation (NASDAQ:DRRX) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws. DURECT Corporation (NASDAQ:DRRX) stock decreased -2.65% and finished the last session at $1.47. The EPS of the stock remained -0.22. Company’s market capitalization is $162.27 billion.

    Shares of pharmaceutical company Chimerix Inc (NASDAQ:CMRX) are rising after the company announced last night that it had reached a deal with the FDA to initiate a pilot trial of its brincidofovir drug for the treatment of adenovirus infections. Reports from CNN and other media outlets earlier this week indicated that Chimerix has been under increasing pressure to help a dying 7-year-old boy from Virginia with the experimental drug. Chimerix Inc (NASDAQ:CMRX) shares closed at $26.40 on last trade day, by gaining 7.40%. Stock 52 week range is $12.96 – $27.00. Company’s market capitalization is $706.54 million.